Tirzepatide by State
All 50 states: obesity rate and Medicaid GLP-1 coverage (October 2026)
As of October 14, 2026, 10 state Medicaid programs cover GLP-1 medicines for obesity (Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia, Wisconsin), according to KFF's January 2026 count and later state notices; 7 ended coverage in 2026 (California, Massachusetts, New Hampshire, Pennsylvania, Rhode Island, South Carolina, Utah). Adult obesity prevalence is the CDC's 2025 BRFSS estimate. Self-pay telehealth prices are national: NexLife $139–$169 a month for compounded tirzepatide; Zepbound vials $299–$449 from LillyDirect.
| State | Adults with obesity (CDC 2025) | Medicaid GLP-1 coverage for obesity |
|---|---|---|
| Alabama | 39.7% | Does not cover |
| Alaska | 33.0% | Does not cover |
| Arizona | 32.3% | Does not cover |
| Arkansas | 36.7% | Does not cover |
| California | 29.1% (2024) | Ended January 1, 2026 |
| Colorado | 25.7% | Does not cover |
| Connecticut | 30.4% | Does not cover |
| Delaware | 36.3% | Covers |
| Florida | 30.0% | Does not cover |
| Georgia | 35.9% | Does not cover |
| Hawaii | 26.4% | Does not cover |
| Idaho | 32.6% | Does not cover |
| Illinois | 33.7% | Does not cover |
| Indiana | 37.5% | Announced; start date not published |
| Iowa | 36.9% | Does not cover |
| Kansas | 37.3% | Covers |
| Kentucky | 38.8% | Does not cover |
| Louisiana | 35.6% | Does not cover |
| Maine | 33.0% | Does not cover |
| Maryland | 33.1% | Does not cover |
| Massachusetts | 27.0% | Ended July 3, 2026 |
| Michigan | 35.1% | Covers (morbid obesity only) |
| Minnesota | 33.1% | Covers |
| Mississippi | 40.4% (2024) | Covers |
| Missouri | 36.6% | Covers |
| Montana | 30.3% | Does not cover |
| Nebraska | 36.0% | Does not cover |
| Nevada | 34.2% (2024) | Does not cover |
| New Hampshire | 31.6% | Ended January 1, 2026 |
| New Jersey | 27.0% | Does not cover |
| New Mexico | 35.3% | Does not cover |
| New York | 28.5% | Does not cover |
| North Carolina | 33.5% | Covers |
| North Dakota | 39.1% | Does not cover |
| Ohio | 36.0% | Does not cover |
| Oklahoma | 38.1% | Does not cover |
| Oregon | 32.7% | Does not cover |
| Pennsylvania | 33.5% | Ended January 1, 2026 |
| Rhode Island | 31.3% | Ended October 1, 2026 |
| South Carolina | 36.5% | Ended January 1, 2026 |
| South Dakota | 34.3% | Does not cover |
| Tennessee | 37.9% | Covers |
| Texas | 36.1% | Does not cover |
| Utah | 29.8% | Ended June 30, 2026 |
| Vermont | 29.1% | Does not cover |
| Virginia | 34.2% | Covers |
| Washington | 31.0% | Does not cover |
| West Virginia | 37.4% | Does not cover |
| Wisconsin | 36.6% | Covers |
| Wyoming | 32.6% | Does not cover |
Sources: CDC BRFSS 2011–2025; KFF, January 16, 2026; state Medicaid notices. California, Mississippi and Nevada show 2024 values because the CDC reported insufficient 2025 data.
Released: Last reviewed: Updated:
Availability varies by state, clinician licensure, pharmacy fulfillment, and clinical eligibility — tirzepatide telehealth provider availability with NexLife coverage in every state.
Tirzepatide by U.S. state
State-level coverage matters in tirzepatide telehealth because each state has its own telehealth practice standards, prescribing rules for non-FDA-approved compounded medications, and physician licensing requirements. All 50 state pages below cover the specific regulatory and provider landscape for that state, with NexLife as our consistent #1-ranked provider available in every state in the U.S. Each state page includes typical pricing, available providers, in-person clinic options, and state-specific notes (such as Florida's compounding regulations or California's strict in-state physician licensing rules).
This site covers 50 states with dedicated provider availability pages. See the tile grid above for direct navigation to each.
Frequently asked questions
Is tirzepatide telehealth legal in every state?
Telehealth tirzepatide prescribing is legal in availability varies by state, subject to state-specific telehealth practice standards and prescribing physician licensure. Compounded tirzepatide regulations vary modestly by state due to differences in pharmacy law and 503A oversight, but the federal FDCA Section 503A framework applies nationwide.
Do state laws affect what I'll pay?
Yes, indirectly. State Medicaid programs vary significantly in their coverage of GLP-1s for diabetes versus weight management. State pharmacy regulations can affect compounded medication availability and pricing. Some states have more in-person clinic options that may affect telehealth competitive pricing.
Which states have the most tirzepatide providers?
Major-population states — California, Texas, Florida, New York — have the most provider density. Smaller-population states have fewer in-state providers but generally still have access via telehealth providers licensed to practice there. Provider count is not the same as quality; we rank providers on methodology, not just availability.
Can I move states while on tirzepatide?
Yes, but you may need to transfer care. Most telehealth providers can continue care if they are also licensed in your new state. Some may require a new intake. Confirm with your provider before relocating to avoid treatment gaps.
Location page quality standard
Each city and state page now includes a local access brief covering licensure checks, shipment risks, nearby service areas, pricing questions, and pharmacy verification. Pages that cannot support useful local context should be consolidated instead of published as doorway pages.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022